Compare Nuwellis Inc (NUWE) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs T Rowe Price Group Inc — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while T Rowe Price Group Inc trades at $104.25 (market cap $22.20B). The key difference: T Rowe Price Group Inc is far larger — about 10090.9× Nuwellis Inc's market cap, and T Rowe Price Group Inc pays a 5% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and T Rowe Price Group Inc for 115 Days on average.
| NUWE | TROW | |
|---|---|---|
Market Cap | $2.20M | $22.20B |
Volume | 121,544 | 1,738,431 |
Sector | Health | Financials |
52-Week High | $146.65 | $121.68 |
52-Week Low | $0.68 | $86.19 |
Typical Hold Time | 26 Days | 115 Days |
Enterprise Value | -$1.52M | $19.39B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
T. Rowe Price (TROW) trades at $104.23, up 0.61% with bearish technical signals but strong fundamentals including a 29.26% net margin and $2.09B net income. The stock shows consistent earnings beats and dividend growth, supported by $1.90 trillion in assets under management as of August 2026. Recent news highlights dividend sustainability and ETF expansion through acquisitions.
Outlook remains positive with a $112 consensus price target offering 7.5% upside, though technical weakness and market volatility pose near-term risks. The company's 40-year dividend growth history and expanding product portfolio provide stability, while net outflows and competitive pressures require monitoring for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
